In this 60-minute webinar, Terri M. Solomon and Dr. Marc McElhaney explain how to prepare for and handle a serious employee mental health crisis that prevents an employee from caring for themselves or puts an employee at risk of hurting themselves or others. The discussion supports SDG 3 (good health and well being).
The pharmacologic parameters that drive optimal HIV latency reversal in vivo are unknown and could be influenced by such factors as the HDACi binding kinetics, concentration of compound, and duration of exposure. This study evaluates how these parameters affect HIV latency reversal for a series of novel HDACis that differ in their enzymatic on and off rates. The comprehensive data set generated by automating the assays described here was used to establish a PK/PD model for HDACi-induced HIV latency reversal.
Main participants in a PPP—core strengths and key benefits in drug discovery/development. The figure provides an overview of the main participants in a PPP, highlights their core strengths, and lists important benefits across the various stages of the dru
Collaborative efforts between public and private entities such as academic institutions, governments, and pharmaceutical companies form an integral part of scientific research, and notable instances of such initiatives have been created within the life science community. Several examples of alliances exist with the broad goal of collaborating toward scientific advancement and improved public welfare. Such collaborations can be essential in catalyzing breaking areas of science within high-risk or global public health strategies that may have otherwise not progressed. A common term used to describe these alliances is public-private partnership (PPP). This review discusses different aspects of such partnerships in drug discovery/development and provides example applications as well as successful case studies. Specific areas that are covered include PPPs for sharing compounds at various phases of the drug discovery process—from compound collections for hit identification to sharing clinical candidates. Instances of PPPs to support better data integration and build better machine learning models are also discussed. The review also provides examples of PPPs that address the gap in knowledge or resources among involved parties and advance drug discovery, especially in disease areas with unfulfilled and/or social needs, like neurological disorders, cancer, and neglected and rare diseases.
This chapter advances the UN SDG Goal 3: Good Health and Goal 10: Reduced Inequalities by elucidating nutrition as a fundamental domain of global health. It highlights the health of individuals and the stability of populations within the academic discipline of global health.
This chapter advances the UN SDG Goal 3: Good Health and Goal 10: Reduced Inequalities by bringing attention to the urgent need for high-quality mental health services and psychosocial support in crisis areas.
In this episode of the “World We Want” podcast series, RELX’s Global Head of Corporate Responsibility, Dr. Márcia Balisciano, talks to Tessy Antony de Nassau about leadership.
This chapter advances the UN SDG goals 3 and 5 by providing an overview of common fungal infections of the mammary gland, which have consequences for mothers and babies.
Elsevier,

Assessments, Treatments and Modeling in Aging and Neurological Disease, May 2021, Pages 115-126

This book chapter advances SDGs 3 and 17 by summarizing the relation between AD, dementia and vascular disease.
Elsevier,

Reference Module in Biomedical Sciences, 2021

Recognizes gender as a complex entity and recommends indivoidualized care approaches for gender diverse patients, especially youth. Supports SDG 5: Achieve gender equality.
Problem: Today, one in four children in the world lives in an area of conflict or disaster, and more than 30 million have been displaced, enslaved or trafficked, abused, and exploited.

Pages